Joachim Brouwers1, Jan Tack, Patrick Augustijns. 1. Laboratory for Pharmacotechnology and Biopharmacy, Katholieke Universiteit Leuven, Gasthuisberg O&N 2-Herestraat 49, box 921, Leuven, Belgium.
Abstract
PURPOSE: The purpose of this study was to explore the feasibility of linking the pharmacokinetic profile of a drug with its gastrointestinal behavior by simultaneously monitoring plasma and intraluminal drug concentrations. Fosamprenavir, a phosphate ester prodrug of the poorly water-soluble HIV-inhibitor amprenavir, was selected as model compound. METHODS: A single tablet of fosamprenavir (Telzir) was administered to 5 volunteers in the fasted and fed state (simulated by intake of a nutritional drink). Gastric and duodenal fluids were aspirated in function of time and characterized with respect to the concentration of (fos)amprenavir, inorganic phosphate and pH. In parallel, blood samples were collected and analyzed for amprenavir. RESULTS: The observed plasma concentration-time profiles suggested a food-induced delay in the absorption of amprenavir: in the fed state, mean tmax increased by more than 150 min compared to the fasted state. A similar delay was seen in the duodenal appearance of fosamprenavir (concentrations in mM-range) and, after dephosphorylation, amprenavir (concentrations below 160 microM). This observation could be related to the behavior of fosamprenavir in the stomach. In the fasted state, gastric dissolution of fosamprenavir started immediately, resulting in a Cmax of 4 +/- 2 mM after 43 +/- 15 min; however, in the fed state, the fosamprenavir concentration remained below 20 microM for the first 90 min after drug intake. The postponed gastric dissolution may be attributed to a food-induced delay in tablet disintegration. CONCLUSION: For the first time, the pharmacokinetic profile of a drug was monitored in parallel with its gastrointestinal concentrations. The observed food effect in the plasma concentration-time profile of amprenavir after intake of its phosphate ester prodrug could be related to a food-induced delay in gastric dissolution of fosamprenavir.
PURPOSE: The purpose of this study was to explore the feasibility of linking the pharmacokinetic profile of a drug with its gastrointestinal behavior by simultaneously monitoring plasma and intraluminal drug concentrations. Fosamprenavir, a phosphate ester prodrug of the poorly water-soluble HIV-inhibitor amprenavir, was selected as model compound. METHODS: A single tablet of fosamprenavir (Telzir) was administered to 5 volunteers in the fasted and fed state (simulated by intake of a nutritional drink). Gastric and duodenal fluids were aspirated in function of time and characterized with respect to the concentration of (fos)amprenavir, inorganic phosphate and pH. In parallel, blood samples were collected and analyzed for amprenavir. RESULTS: The observed plasma concentration-time profiles suggested a food-induced delay in the absorption of amprenavir: in the fed state, mean tmax increased by more than 150 min compared to the fasted state. A similar delay was seen in the duodenal appearance of fosamprenavir (concentrations in mM-range) and, after dephosphorylation, amprenavir (concentrations below 160 microM). This observation could be related to the behavior of fosamprenavir in the stomach. In the fasted state, gastric dissolution of fosamprenavir started immediately, resulting in a Cmax of 4 +/- 2 mM after 43 +/- 15 min; however, in the fed state, the fosamprenavir concentration remained below 20 microM for the first 90 min after drug intake. The postponed gastric dissolution may be attributed to a food-induced delay in tablet disintegration. CONCLUSION: For the first time, the pharmacokinetic profile of a drug was monitored in parallel with its gastrointestinal concentrations. The observed food effect in the plasma concentration-time profile of amprenavir after intake of its phosphate ester prodrug could be related to a food-induced delay in gastric dissolution of fosamprenavir.
Authors: Niclas Petri; Christer Tannergren; Birgit Holst; Fred A Mellon; Yongping Bao; Geoff W Plumb; Jim Bacon; Karen A O'Leary; Paul A Kroon; Lars Knutson; Patrik Forsell; Thomas Eriksson; Hans Lennernas; Gary Williamson Journal: Drug Metab Dispos Date: 2003-06 Impact factor: 3.922
Authors: Christine Falcoz; Julian M Jenkins; Carole Bye; Timothy C Hardman; Kathy B Kenney; Scott Studenberg; H Fuder; William T Prince Journal: J Clin Pharmacol Date: 2002-08 Impact factor: 3.126
Authors: Eric S Furfine; Christopher T Baker; Michael R Hale; David J Reynolds; Jo A Salisbury; Andy D Searle; Scott D Studenberg; Dan Todd; Roger D Tung; Andrew Spaltenstein Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Sarah Clarysse; Dimitrios Psachoulias; Joachim Brouwers; Jan Tack; Pieter Annaert; Guus Duchateau; Christos Reppas; Patrick Augustijns Journal: Pharm Res Date: 2009-03-07 Impact factor: 4.200
Authors: Tong Lu; Grazyna Fraczkiewicz; Laurent Salphati; Nageshwar Budha; Gena Dalziel; Gillian S Smelick; Kari M Morrissey; John D Davis; Jin Y Jin; Joseph A Ware Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-10-17